Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Emergence of Carbapenemase-Producing Enterobacteriaceae, South-Central Ontario, Canada1.

Kohler PP, Melano RG, Patel SN, Shafinaz S, Faheem A, Coleman BL, Green K, Armstrong I, Almohri H, Borgia S, Borgundvaag E, Johnstone J, Katz K, Lam F, Muller MP, Powis J, Poutanen SM, Richardson D, Rebbapragada A, Sarabia A, Simor A, McGeer A; Toronto Invasive Bacterial Diseases Network (TIBDN).

Emerg Infect Dis. 2018 Sep;24(9):1674-1682. doi: 10.3201/eid2409.180164.


Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae.

Cheng MP, Bogoch II, Green K, Plevneshi A, Rudnick W, Shigayeva A, McGeer A, Lee TC; Toronto Invasive Bacterial Diseases Network .

Clin Infect Dis. 2018 Apr 3;66(8):1282-1285. doi: 10.1093/cid/cix999.


Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.

Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM.

Clin Infect Dis. 2017 Feb 1;64(3):265-271. doi: 10.1093/cid/ciw731. Epub 2016 Nov 9.


Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003-2011.

Shigayeva A, Rudnick W, Green K, Tyrrell G, Demczuk WH, Gold WL, Gubbay J, Jamieson F, Plevneshi A, Pong-Porter S, Richardson S, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2016 Feb 3;34(6):846-53. doi: 10.1016/j.vaccine.2015.11.021. Epub 2015 Nov 18.


Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.

Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M, Powis J, Rau N, Walmsley S, Tyrrell G, Bitnun A, McGeer A; Toronto Invasive Bacterial Diseases Network.

Clin Infect Dis. 2016 Jan 15;62(2):139-47. doi: 10.1093/cid/civ803. Epub 2015 Sep 9.


Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2013 Dec 2;31(49):5863-71. doi: 10.1016/j.vaccine.2013.09.049. Epub 2013 Oct 5.


Efficacy of admission screening for extended-spectrum beta-lactamase producing Enterobacteriaceae.

Lowe CF, Katz K, McGeer AJ, Muller MP; Toronto ESBL Working Group.

PLoS One. 2013 Apr 26;8(4):e62678. doi: 10.1371/journal.pone.0062678. Print 2013.


Disparity in infection control practices for multidrug-resistant Enterobacteriaceae.

Lowe C, Katz K, McGeer A, Muller MP; Toronto ESBL Working Group.

Am J Infect Control. 2012 Nov;40(9):836-9. doi: 10.1016/j.ajic.2011.11.008. Epub 2012 Feb 22.


A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.

Vaccine. 2009 Sep 25;27(42):5913-9. doi: 10.1016/j.vaccine.2009.07.038. Epub 2009 Aug 3.


Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.

Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simões EA, Wright PF, Sales VM.

J Infect Dis. 2008 Nov 1;198(9):1317-26. doi: 10.1086/592168.


Respiratory syncytial virus vaccine: Is it coming?

Sales V, Wang EE.

Paediatr Child Health. 2003 Dec;8(10):605-8.

Supplemental Content

Loading ...
Support Center